EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation

Alberto Antonicelli, Stefano Cafarotti, Alice Indini, Alessio Galli, Andrea Russo, Alfredo Cesario, Filippo Maria Lococo, Patrizia Russo, Alberto Franco Mainini, Luca Giuseppe Bonifati, Mario Nosotti, Luigi Santambrogio, Stefano Margaritora, Pierluigi Maria Granone, André Emanuel Dutly, Alberto Antonicelli, Stefano Cafarotti, Alice Indini, Alessio Galli, Andrea Russo, Alfredo Cesario, Filippo Maria Lococo, Patrizia Russo, Alberto Franco Mainini, Luca Giuseppe Bonifati, Mario Nosotti, Luigi Santambrogio, Stefano Margaritora, Pierluigi Maria Granone, André Emanuel Dutly

Abstract

The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS. Actually, the value of EGFR expressed in patients with NSCLC in predicting a benefit in terms of survival from treatment with an epidermal growth factor receptor targeted therapy is still in debate, while there is a convincing evidence on the predictive role of the EGFR mutational status with regard to the response to tyrosine kinase inhibitors (TKIs).This is a literature overview on the state-of-the-art of EGFR oncogenic mutation in NSCLC. It is designed to highlight the preclinical rationale driving the molecular footprint assessment, the progressive development of a specific pharmacological treatment and the best method to identify those NSCLC who would most likely benefit from treatment with EGFR-targeted therapy. This is supported by the belief that a rationale for the prioritization of specific regimens based on patient-tailored therapy could be closer than commonly expected.

Keywords: EGFR targeted therapy; NSCLC; TKIs; advanced; mutation; resistance..

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Ways to leave your EGFR inhibitor: Biochemical pathways leading to resistance to small molecule EGFR drugs such as gefitinib and erlotinib. (A) Structures of two approved EGFR TKIs, gefitinib and erlotinib, used in the treatment of NSCLC. (B) Ribbon diagram of wild-type human EGFR (PDB code 2ITY), illustrating binding of gefitinib to the active site of the kinase. The magenta ball-stick (located just above the gefitinib molecule in the active site) indicates the gatekeeper residue (threonine790) that is commonly mutated to methionine (T790M), resulting in reduced inhibitor binding and drug resistance. (C) Simplified pathway diagram of EGFR signaling through RAS/MEK/ERK and PI3K/PDK1/AKT indicating the points of mutation/amplification in EGFR TKI resistance as reported by Sequist and colleagues. The resistance mechanisms include the EGFR T790M gatekeeper mutation, amplification of EGFR T790M, MET amplification, and PI3KCA mutation (note that additional epithelial to mesenchymal transition changes and transformation from the NSCLC to the SCLC phenotype also lead to resistance but are not covered by this illustration). The illustration also shows the FAS/NF-kB signaling arm downstream of the FAS death receptor that was shown to be important in TKI resistance by Bivona and colleagues. Reprinted from Cancer Cell, 19, Paul Workman and Paul A. Clarke, “Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR”, 437-440, 2011, with permission from Elsevier.

References

    1. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol. 2003;30:3–14.
    1. Paez JG, Janne PA, Lee JC. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2002;304:1497–1500.
    1. Lynch TJ, Bell DW, Sordella R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib therapy. N Engl J Med. 2004;350:2129–2139.
    1. Cheng L, Zhang S, Alexander R. et al. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncol. 2011;7:519–541.
    1. Normanno N, De Luca A, Bianco C. et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366:2–16.
    1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–354.
    1. HirschFR Varella-Garcia M, Capuzzo. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene. 2009;28:S32–S37.
    1. Quesnelle KM, Boehm AL, Grandis JR. STAT-mediated EGFR signaling in cancer. J Cell Biochem. 2007;102(2):311–9.
    1. Wang X, Zhang S, MacLennan GT. et al. Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma. Mod Pathol. 2008;22:7–12.
    1. Wang X, Zhang S, MacLennan GT. et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res. 2007;13:953–957.
    1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–1380.
    1. Costa DB, Halmos B, Kumar A. et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007;4:1669–1679.
    1. Sharma SV, Haber DA, Settleman J. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169–181.
    1. Sequist LV, Bell DW, Lynch TJ. et al. Molecular predictor of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J ClinOncol. 2007;25:587–595.
    1. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008;21(Suppl 2):S16–S22.
    1. Shigematsu H, Lin L, Takahashi T. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancer. J Natl Cancer Inst. 2005;97:339–346.
    1. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. The Lancet Oncology. 2011;12:175–180.
    1. Yamamoto H, Toyooka S, Mitsudomi T. Impact of EGFR mutation analysis in non-small-cell lung cancer. Lung Cancer. 2009;63:315–321.
    1. Eberhard DA, Johnson BE, Amler LC. et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J ClinOncol. 2005;23:5900–5909.
    1. Schrump DS, Altorki NK, Henschke CL, et al. Non-small cell lung cancer. In: DeVita VT, editor. Cancer: Principles and Practices of Oncology. Philadelphia: Lippincott Williams & Wilkins; 2005. pp. 753–810.
    1. Azzoli CG, Baker Jr S, Temin S. et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27:6251–6266.
    1. Fossella F, Pereira JR, von Pawel J. et al. Randomized, multinational phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J ClinOncol. 2003;21:3016–3022.
    1. Sandler A, Gray R, Perry MC. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.
    1. Shepherd FA, Dancey J, Ramlau R. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103.
    1. Hanna N, Shepherd FA, Fossella FV. et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J ClinOncol. 2004;22:1589–1597.
    1. Shepherd FA, Rodrigues PJ, Ciuleanu T. et al. Erlotinib in previously treated non-small-cell lung cancer. NEngl J Med. 2005;353:123–132.
    1. Lynch TJ, Bell DW, Sordella R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139.
    1. Paez JG, Janne PA, Lee JC. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500.
    1. Fujita S, Katakami N, Masago K. et al. Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial. BMC Cancer. 2012;12:185.
    1. Soria JC, Mok TS, Cappuzzo F, Pasi AJ. EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. Cancer treatment reviews. 2012;38:416–430.
    1. Zhu J, Zhong W, Zhang G. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Lett. 2008;265(2):307–17.
    1. Cappuzzo F, Varella-Garcia M, Shigematsu H. et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. Journal of Clinical Oncology. 2005;23:22.
    1. Pirker R, Pereira JR, von Pawel J. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012;13:33–42.
    1. Wang M, Zhao J, Zhang LM. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer. J Cancer Res Clin Oncol. 2012;138(12):2069–77.
    1. Kim HP, Han SW, Kim SH. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol Cancer Ther. 2008;7(3):607–15.
    1. Mok TS, Wu YL, Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957.
    1. Maemondo M, Inoue A, Kobayashi K. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388.
    1. Zhu CQ, da Cunha Santos G, Ding K. et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J ClinOncol. 2008;26:4268–4275.
    1. Kim ES, Hirsh V, Mok T. et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372:1809–1818.
    1. Costa DB, Kobayashi S, Tenen DG. et al. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small-cell lung cancer. Lung Cancer. 2007;58:95–103.
    1. Rosell R, Moran T, Queralt C. et al. Screening for epidermal growth factor mutations in lung cancer. N Engl J Med. 2009;361:958–967.
    1. Sequist LV, Martins RG, Spigel D. et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008;26:2442–2449.
    1. Tamura K, Okamoto I, Kashii T. et al. Multicentre prospective phase II trial of gefitinib for advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) Br J Cancer. 2008;98:907–914.
    1. Mok T, Wu YC, Thongprasert S. et al. Phase III, randomised, open-label, first-line study gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non-small-cell lung cancer (NSCLC) (IPASS) Ann Oncol. 2008;19:AbstractLBA2.
    1. Mitsudomi T, Morita S, Yatabe Y. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–128.
    1. Inoue A, Suzuki T, Fukuhara T. et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small cell lung cancer with epidermal growth factor mutations. J ClinOncol. 2006;24:3340–3346.
    1. Asahina H, Yamazaki K, Kinoshita I. et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor. Br J Cancer. 2006;95:998–1004.
    1. Yoshida K, Yatabe Y, Park JY. et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol. 2007;2:22–28.
    1. Sugio K, Uramoto H, Onitsuka T. et al. Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer. 2009;64:314–318.
    1. Zhou C, Wu Y-L, Chen G. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–742.
    1. Rosell R, Carcereny E, Gervais R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–246.
    1. Scheffler M, Di Gion P, Doroshyenko O. et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. ClinPharmacokinet. 2011;50(6):371–403.
    1. Ettinger DS, Akerley W, Bepler G. et al. Non-small-cell lung cancer. J NatlComprCancNetw. 2010;8:740–801.
    1. Thongprasert S, Duffield E, Saijo N. et al. Health-related quality-of-life in a randomized fase III first-line study of Gefitinib versus Carboplatin/Paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS) J ThoracOncol. 2011;6:1872–1880.
    1. Keedy VL, Temin S, Somerfield MR. et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR Tyrosine kinase inhibitor therapy. J ClinOncol. 2011;29:2121–2127.
    1. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009;10:281–289.
    1. Jackman D, Pao W, Riely GJ. et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28:357–360.
    1. Suda K, Onozato R, Yatabe Y. et al. EGFR T790M mutation: a double role in lung cancer survival? J Thorac Oncol. 2009;4:1–4.
    1. Pao W, Miller VA, Politi KA. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73.
    1. Yun CH, Mengwasser KE, Toms AV. et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. ProcNatlAcadSci USA. 2008;105:2070–2075.
    1. Bean J, Riely GJ, Balak M. et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res. 2008;14:7519–7525.
    1. Balak MN, Kwak EL, Shaw AT. et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006;12:6494–6501.
    1. Maheswaran S, Sequist LV, Nagrath S. et al. Detection of mutations in EGFR in circulating lung cancer cells. N Engl J Med. 2008;359:366–377.
    1. Ayoola A, Barochia A, Belani K, Belani C. Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest. 2012;30(5):433–446.
    1. Su KY, Chen HY, Li KC. et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small cell lung cancer. J Clin Oncol. 2012;30(4):433–440.
    1. Chen HJ, Mok TS, Chen ZH. et al. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non small cell lung cancer. PatholOncol Res. 2009;15:651–658.
    1. Viloria-Petit A, Crombet T, Jothy S. et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001;61:5090–5101.
    1. Guix M, Faber AC, Wang SE. et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 2008;118:2609–2619.
    1. Okudela K, Suzuki M, Kageyama S. et al. PIK3CA mutation and amplification in human lung cancer. PatholInt. 2007;57:664–671.
    1. Yamamoto H, Shigematsu H, Nomura M. et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 2008;68:6913–6921.
    1. Sequist LV, Waltman BA, Dias-Santagata D. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. SciTransl Med. 2011;3:75ra26.
    1. Ohashi K, Sequist LV, Arcila ME. et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. ProcNatlAcadSci U S A. 2012;109(31):E2127–33.
    1. Linardou H, Dahabreh IJ, Kanaloupiti D. et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9(10):962–72.
    1. Pesek M, Benesova L, Belsanova B. et al. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Anticancer Res. 2009;29(7):2767–73.
    1. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor- targeted therapy? J Clin Oncol. 2010;28(31):4769–77.
    1. Sequist LV, Besse B, Lynch TJ. et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of phase II trial in patients with advanced non small-cell lung cancer. J Clin Oncol. 2010;28:3076–3083.
    1. Miller VA, Hirsch V, Cadranel J. et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13:528–538.
    1. Yang C, Shih J, Su W. et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012;13:539–548.
    1. Engelman JA, Zejnullahu K, Gale CM. et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancers models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007;67:11924–11932.
    1. Boyer MJ, Blackhall FH, Park K. et al. Efficacy and safety of PF00299805 versus erlotinib: a global, randomised phase 2 trial in patients with advanced non small cell lung cancer after failure of chemotherapy. In: Proceedings of 46th Annual Meeting of the American Society of Clinical Oncology. J Clin Oncol. 2010;28(15 Suppl):abstractLBA7523.
    1. Takahashi T, Boku N, Murakami H. et al. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Invest New Drugs. 2012 Epub ahead of print.
    1. Ramalingam SS, Blackhall F, Krzakowski M. et al. Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. J ClinOncol. 2012;30(27):3337–3344.
    1. Tanner NT, Pastis NJ, Sherman C. et al. The role of molecular analyses in the era of personalized therapy for advanced NSCLC. Lung Cancer. 2012;76:131–137.
    1. Warth A, Penzel R, Brandt R. et al. Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Arch. 2012;460(4):407–14.
    1. Pareek C, Smoczynski R, Tretyn A. Sequencing technologies and genome sequencing. J Appl Genet. 2011;52(4):413–435.
    1. Su Z, Ning B, Fang H. Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn. 2011;11(3):333–43.
    1. Giaccone G, Wang Y. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev. 2011;37(6):456–464.
    1. Luping Lin, Trever G. Bivona. Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients. Chemother Res Pract. 2012 Epub ahead of print.
    1. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(Suppl 1):S24–S31.
    1. Varella-Garcia M, Diebold J, Eberhard DA. et al. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol. 2009;62(11):970–977.
    1. Pallis AG, Fennell DA, Szutowicz E. et al. Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. Br J Cancer. 2011;105(1):1–8.
    1. Zhang X, Chang A. Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci. 2008;5(4):209–217.
    1. Lim EH, Zhang SL, Yu K. et al. An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): maximizing the diagnostic procedure and the use of low-volume lung biopsies. J ThoracOnco. 2007;2:387–396.
    1. Shih JY, Gow CH, Yu CJ. et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced non small cell lung cancer. Int J Cancer. 2006;118:963–969.
    1. Sunaga N, Tomizawa Y, Yanagitani N. et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer. 2007;56:383–389.
    1. Nakajima T, Yasufuku K, Sufuku M. et al. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest. 2007;132:597–602.
    1. Yoshida K, Yatabe Y, Park JY. et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol. 2007;2:22–28.
    1. Garcia-Olivè I, Monsò E, Andreo F. et al. Endobronchial ultrasound-guidedtransbronchial needle aspiration for identifying EGFR mutations. Eur Respir J. 2010;35:391–5.
    1. Fassina A, Gazziero A, Zardo D. et al. Detection of EGFR and KRAS mutations ontrans-thoracic needle aspiration of lung nodules by high resolution melting analysis. J ClinPathol. 2009;62:1096–1102.
    1. Ellison G, Zhu G, Moulis A. et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2012;0:1–11.
    1. Kimura H, Kasahara K, Shibata K. et al. EGFR mutation of tumor and serum ingefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J ThoracOncol. 2006;1:260–267.
    1. Kim KS, Jeong JY, Kim YC. et al. Predictors of the response to gefitinib in refractorynon-small cell lung cancer. Clin Cancer Res. 2005;11:2244–2251.
    1. Mack PC, Holland WS, Burich RA. et al. EGFR mutations detected in plasma areassociated with patient outcomes in erlotinib plus docetaxel-treated non-small celllung cancer. J ThoracOncol. 2009;4:1466–1472.
    1. Mattsson JS, Imgenberg-Kreuz J, Edlund K. et al. Consistent mutation status within histologically heterogeneous lung cancer lesions. Histopathology. 2012;61(4):744–748.
    1. Chen ZY, Zhong WZ, Zhang XC. et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist. 2012;17(7):978–85.
    1. Sun L, Zhang Q, Luan H. et al. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J ExpClin Cancer Res. 2011;30(1):30.
    1. Jakobsen JN, Sorensen JB. Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer. Cancer ChemotherPharmacol. 2012;69(2):289–99.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere